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Abstract 
Due to their similar aetiologies, cardiovascular disease and erectile dysfunction are closely 
linked, with the prevalence of erectile dysfunction being approximately 75% for individuals 
at high risk of cardiovascular disease. Erectile dysfunction can have a detrimental effect on 
quality of life not only for the individual but also his sexual partner which in turn impacts 
upon their intimate relationship. Some cardiovascular disease medications have been found 
to have a negative effect on erectile function and therefore act as an influential factor for 
the cessation of important cardiovascular disease medication. Low adherence to 
cardiovascular disease medication has been linked to increased health costs, 
hospitalizations and importantly, a higher risk of mortality. Research has shown that men 
find it difficult to seek medical help in relation to ED which is also compounded by the 
notion that health care providers do not address sexual issues adequately. Patients͛ beliefs 
about cardiovascular disease medication are modifiable and therefore an opportunity exists 
not only for health care providers to facilitate discussions in relation to erectile dysfunction 
and medication adherence but also encompass an opportunity to increase adherence to 
cardiovascular disease medication through intervention. 
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Introduction  
Erectile Dysfunction (ED) is the persistent inability to attain and maintain a penile erection 
adequate for sexual performance (Kloner, 1993). A recent review that collated results from 
59 studies from across the globe suggests that the prevalence of ED increases with age. 
Estimations range from 20 – 40% for men 60 – 69 years and 50 – 100% foƌ ŵeŶ iŶ theiƌ ϳϬ͛s 
aŶd ϴϬ͛s (Lewis et al, 2010). Estimations of prevalence vary widely however, due to: the 
definition of ED that is used; the population studied; and the method by which ED is 
measured (Rosen et al, 1999; Lewis et al, 2010).  
 
Cardiovascular disease (CVD) and ED share a similar disease profile in relation to their 
aetiology and risk factors. Vascular diseases have been documented as the most common 
cause of ED (Hodges et al, 2007) and both share risk factors such as obesity, diabetes 
mellitus, physical inactivity, hypertension, dyslipidaemia and tobacco usage (Ponholzer et al, 
2005). Exposure to such risk factors can result in the build-up of plaque around arteries or 
atherosclerosis, which can in turn lead to CVD. Arteries in the penis are small (around 1 – 2 
mm) in comparison to e.g. coronary arteries (around 3 – 4 mm) (Jackson, 2013) and as a 
result, arteries in the penis suffer obstruction caused by atheromatous plaque earlier than 
coronary arteries or indeed other arteries. Therefore ED is typically experienced before the 
onset of a cardiac event and is regarded as an indication of the presence of CVD (Montorsi 
et al, 2003). Solomon et al (2003) found that 40% of men experience ED before they are 
diagnosed as suffering from coronary artery disease (CAD). Further, a retrospective cohort 
study of 26,000 participants found a two-fold increase in risk of myocardial infarction at 1 
year follow-up for 13,000 men who reported ED at baseline (Blumentals et al, 2004). 
Baumhäkel et al (2006) suggest that the prevalence of ED equates to 75% for individuals at 
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high-risk of CVD. Studies such as these indicate not only a relationship between ED and CVD 
but also that ED is an important indicator of increased CVD risk.  
 
The aim of this paper is twofold. Firstly, the paper will consider both CVD, ED and the 
contemporary understanding of the link that exists between the two conditions. Further, 
the similarities between their disease profiles such as their risk factors and aetiologies will 
be considered. Secondly, adherence to CVD medication regimes and the mediating role of 
ED will be considered. The impact of suffering with CVD and ED will be approached from the 
individual level and will consider both help-seeking behaviour and quality of life. Finally, 
suggestions are offered in relation to the role future research could take in exploring the 
link between ED and adherence to CVD medication.  
 
Cardiovascular Disease  
Cardiovascular disease (CVD) includes all diseases of the heart and circulatory system, 
including coronary heart disease (angina and myocardial infarction), heart failure, congenital 
heart disease and stroke (BHF, 2013). CVD is the number one cause of mortality, responsible 
for 17.3 million (30%) of total deaths worldwide in 2008 (WHO, 2013).  
 
The Relationship between CVD and ED 
From the onset of ED, the mean time to a cardiac event such as coronary artery disease 
(CAD), myocardial infarction or stroke, is approximately three years (Jackson, 2013). This 
highlights the importance of diagnosing ED as early as possible and provides an important 
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window of opportunity in which preventative action can be taken to avoid a potential 
cardiac event. For health care professionals, this provides an important opportunity to 
identify any underlying CVD in patients. Therefore it is essential to discuss ED with the 
patient at the earliest possible opportunity (refer to Box 1).  
 
Insert box 1 
 
Studies have shown that ED, after controlling for age, body mass index (BMI), blood 
pressure, diabetes, cholesterol and smoking, is likely to be an independent risk factor for 
CVD. In a meta-analysis of 12 prospective cohort studies, Dong et al (2011) found that ED 
was shown to significantly increase the risk of CVD, stroke, CAD and all-cause mortality. The 
severity of CVD has also been shown to correlate with the severity of ED. For example, men 
with single vessel CAD have been found to experience firmer erections than men with two 
or three vessel CAD (Johannes et al, 2000). The severity of ED can be indicated by using the 
5-item International Index of Erectile Function (IIEF-5) (Rosen et al, 1997; 1999, refer to box 
2). The severity of ED is classified with these breakpoints: score of 1-7 = severe ED; score of 
8-11 = moderate ED; score of 12-16 = mild to moderate ED; score of 17-21 = mild ED. Scores 
>Ϯϭ iŶdiĐate ͚Ŷoƌŵal͛ erectile function (Cappelleri and Rosen, 2005). Using an instrument 
such as the IIEF-5 can help to identify both the presence of ED and also be used as an  entry 
point into discussing adherence with CVD medication. Baumhäkel et al (2011) suggest that 
in the last four decades both the medical press and lay media have reported an association 
between drugs used for treating CVD and their negative effect on erectile function. 
Baumhäkel et al (2011) contend that this has had an impact on patient adherence to 
important cardiovascular medical regimes. 
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Insert box 2 
 
Adherence 
Unwanted or unused medication is estimated to cost the National Health Service (NHS) in 
excess of £100 million annually (Nunes et al, 2009). The cost of CVD medication to the NHS 
is approximately £2.8 billion per annum which constitutes 20% of the health care costs 
associated with CVD (Knapton, 2012). This figure becomes salient in light of research such as 
that of Naderi et al (2012) who carried out a meta-analysis of 376,162 patients with CVD and 
found that approximately 50% of individuals do not take CVD medication as prescribed. 
 
Adherence to CVD medications can involve a complex interplay of patient and treatment 
characteristics (Munger et al, 2007). Factors that have been suggested to influence non-
adherence to CVD medication include being of a younger age (Hassan et al, 2005), suffering 
with depression (Aggarwal and Mosca, 2010), complexity of the prescription regimen 
(Grégoire et al, 2006), beliefs about necessity (Ruppar et al, 2012), beliefs about medication 
(Benson and Britten, 2002; Ogedegbe et al, 2004; Fergus, 2009) and beliefs about the 
severity of CVD (Stafford et al, 2008).  
 
Voils et al (2008) carried out a qualitative study of 38 male hypertensive patients and 13 
spouses. Sexual dysfunction emerged as a factor preventing people from taking their 
antihypertensive medication as prescribed. Participants reported ceasing their medication 
or missing doses to preserve erectile function, however, Voils et al (2008) did not report 
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which antihypertensive medications participants were taking. In a randomised placebo-
controlled trial of the thiazide diuretic, bendrofluazide, and the beta-blocker, propranolol, 
ED as a reason for withdrawal from treatment was significantly higher in both treatment 
groups than in the placebo (MRC, 1985). Baumhäkel et al (2011) examined the evidence for 
the effect of ACE-inhibitors, angiotensin-receptor-blockers, beta blockers, calcium channel-
blockers, and diuretics on erectile function. They concluded that thiazide diuretics and beta-
blockers (excluding nebivolol) may have an adverse effect on erectile function; however 
they report that ACE-inhibitors, angiotensin-receptor-blockers and calcium channel-blockers 
have no effect and in fact potentially have a positive effect. It has also been suggested that 
the effect of beta-blockers on ED may be partly related to patient expectations about side 
effects.  
 
The notion that patient beliefs about CVD medications and erectile function can potentially 
impact upon response to medication has been explored by studies such as Silvestri et al 
(2003). In a cohort of 96 men prescribed atenolol for CVD, one third were not advised which 
drug they had been given, one third were advised of the drug but not told about ED as a 
potential side effect and the remaining third were informed about the drug and the side 
effect. ED was reported in 3.1%, 15.6% and 31.2% of the groups respectively. At the end of 
the 90-day treatment period, those reporting ED were randomised to receive sildenafil 
citrate or a placebo, which were reported to be equally effective, although it must be borne 
in mind that the sample size was very small. 
 
The tǇpe of ŵediĐatioŶ pƌesĐƌiďed aŶd patieŶts͛ peƌĐeptioŶs in relation to side effects are 
therefore important factors to consider in non-adherence to CVD medication (Vlachopoulos 
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et al, 2013). If patients believe that CVD medications impair their sexual function they may 
be less likely to adhere to treatment; non adherence has serious consequences, in relation 
to increased health costs, hospitalisation, as well as increased morbidity and mortality 
(Baroletti et al, 2010). It is important therefore that healthcare professionals discuss ED with 
patients so that they can identify concerns, clarify any misconceptions and choose the most 
suitable treatments. Scranton et al (2013) suggests that such discussions are important 
because they have the potential to lead to improved adherence to CVD medication. An 
observational study by McLaughlin et al ;ϮϬϬ5Ϳ eǆaŵiŶed ŵeŶ͛s pƌesĐƌiptioŶ Đlaiŵs foƌ 
antihypertensive, oral hypoglycaemic, lipid lowering or antidepressant medication in the 12 
months before and 12 months after they were first prescribed sildenafil citrate. Patients 
classified as non-adherent (a medication possession ratio of <0.8, which means that less 
than 80% of doses were collected from the pharmacy) before being prescribed sildenafil 
citrate were more likely to have been prescribed antihypertensive and antidepressant 
medications. McLaughlin et al (2005) found that in the period after sildenafil citrate was 
prescribed, adherence to all the comorbid medications increased significantly.  
 
Help-seeking 
 
Research from Kirby et al (2001) found that out of 980 men consulting a clinician for help in 
relation to ED, 60% had lipid abnormalities, 18% were suffering with undiagnosed 
hypertension and 5% had ischemic heart disease. One possible reason for such diseases 
going undiagnosed can be found in studies such as that of Laumann et al (2009), who found 
that less than 25% of men actively seek treatment for ED. Avoiding medical help has been 
attributed to embarrassment, difficulties accepting ED as a consequence of ageing or 
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disease, as well as the expectation that healthcare professionals should be responsible for 
broaching the subject (Steggall et al, 2006). Further, Steggall (2012) suggests that the 
terminology used to describe ED may not be understood by all patients, they may not know 
which words are appropriate to use when describing the problem and therefore will not 
approach the issue with their health professional. A further barrier to effective 
communication includes language. The term ED does not easily translate into languages 
such as Bengali and therefore an alternative term may be needed for patients whose first 
language is not English (Steggall, 2009).  
 
Byrne et al (2013) carried out research into both male and female patieŶts͛ aŶd theiƌ ĐaƌdiaĐ 
healthcare providers͛ experiences of communication in relation to sexual issues. They found 
that sexual issues were more likely to be addressed in hospital cardiac rehabilitation settings 
rather than in general practice. The majority of cardiac rehabilitation staff as well as patients 
reported that they believed sexual issues were poorly addressed within their service. 
Patients felt that it would be easy to discuss such issues and reported a desire for more 
opportunities during consultations to discuss sex with their healthcare provider. It is 
interesting to note that patients identified embarrassment as their greatest barrier when 
discussing sexual health issues, while simultaneously heath providers reported that they 
feared causing patients discomfort and anxiety. Therefore, this simultaneous desire to avoid 
upsetting or embarrassing one another needs to be addressed as it has important 
implications for not only for diagnosing and managing both ED and CVD, but also in relation 
to the consequences that CVD aŶd ED ĐaŶ haǀe oŶ aŶ iŶdiǀidual͛s ƋualitǇ of life.  
10 
 
 
Psychosocial well-being  
CVD has ďeeŶ fouŶd to iŵpaĐt sigŶifiĐaŶtlǇ oŶ a peƌsoŶ͛s psǇĐhologiĐal ǁell-being including 
their quality of life and mood (Ôunpuu et al, 2001). A key component of quality of life is an 
iŶdiǀidual͛s seǆualitǇ aŶd foƌ ŵeŶ, aŶ iŵpoƌtaŶt aspeĐt of seǆualitǇ is the aďilitǇ to haǀe aŶd 
maintain an erection in order to carry out sexual intercourse. Kushiro et al (2005) 
investigated the impact of ED on health-related quality of life in a group of patients with 
hypertension and compared them to a matched normotensive control group. Whereas men 
with hypertension only had lower scores on general health compared to those without 
hypertension, men with ED had significantly lower scores in physical, mental health, 
emotional, vitality, and general health-related quality of life compared to those without ED. 
This suggests that ED has a more serious impact on quality of life than hypertension; 
interestingly men living with both hypertension and ED scored the lowest in relation to 
quality of life compared to all other groups.  
 
Depression is recognised as a particularly important factor in understanding the relationship 
between ED and CVD. Men, post myocardial infarction, are likely to experience a significant 
amount of distress and are also more likely to have ED despite age, current medication, 
smoking, weight and other co-morbidities (Vacanti and Caramelli, 2005). Research suggests 
that almost 40% of men with CVD experience co-morbid ED and depression (Lemogne et al, 
2010). However, the impact of this co-morbid triad is complicated; not only are men with 
depression more likely to develop chronic heart disease (CHD) and ED, older men with CHD 
and ED are more likely to suffer from depression (Tan and Pu, 2003).  Epidemiological 
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research suggests that these three conditions overlap (Feldman et al, 1994) and therefore 
presentation of one should trigger further investigations of one or both other conditions.  
 
To understand the overlap between CVD, ED and depression, Goldstein (2000) proposed an 
integrated model (See figure 1) in order to understand that depressive illness, CVD and ED 
share many of the same risk factors and etiological associations. The model highlights the 
potential impact of psychosocial well-being, treatment, overall health status, personal 
characteristics and lifestyle behaviours in aetiology and the cyclical relationship between 
these co-morbid conditions. Goldstein (2000) suggests that a practical implication of the 
model is that patients presenting with symptoms of ED should be routinely screened for 
symptoms of depression and CVD. Equally those that present with depressive symptoms 
should be screened for ED and CVD. Clinicians involved in the management of sexual 
dysfunction are encouraged to be particularly sensitive to the potential comorbidity of CVD 
and depression as well as the potential increased risk of cardiac morbidity and mortality in 
patients with such conditions (Goldstein, 2000).  
 
Insert Figure 1.  
 
Research has been conducted that supports the theory that ED in CVD is independently 
associated with depressive symptoms (Lemogne et al, 2010). Further work has also linked 
this relationship to overall quality of life. In order to estimate the prevalence of sexual 
disorders and depressive symptoms in patients attending cardiac rehabilitation and examine 
the association between sexual disorders, depressive symptoms and quality of life, Kriston 
et al (2010) carried out a survey involving 395 male participants. It was found that 20% had 
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moderate to severe ED and 14% of the sample had moderate or severe depression. It was 
found that impaired sexual functioning was moderately associated with decreased quality of 
life and this relationship was mediated by depression.   
 
In addition to depression, anxiety and specifically performance anxiety can have a significant 
impact on the ability of men to resume sexual activity and function after a cardiac event. 
This may be further amplified if a couple had interpersonal or sexual difficulties prior to the 
cardiac event. Friedman (2000) suggests that cardiac rehabilitation should integrate sexual 
activity in discussions around regaining and maintaining quality of life and this should 
iŶĐlude a patieŶt͛s seǆual paƌtŶeƌ (Friedman, 2000). Partner involvement in the 
rehabilitation process is particularly important given the impact ED can have on intimate 
relationships. Fisher et al (2005) carried out a study of a general sample of men with ED and 
their partners. Self-reported severity of ED by both males and their respective partners were 
found to be highly correlated. Both partners reported dramatic reductions in sexual activity 
after the onset of ED, compared to retrospective reports prior to onset. Research carried 
out by Günzler et al (2009), used self-report methods to investigate sexual problems in a 
sample of men attending cardiac rehabilitation. Sexual problems were associated with 
greater engagement in quarrelling, significantly less tenderness and communication as well 
as poorer quality of partnership in comparison to men without sexual problems. In addition, 
orgasmic function, sexual desire, intercourse satisfaction, overall sexual satisfaction and ED 
were significantly correlated with aspects of partnership quality indicating that as sexual 
functioning improved so did partnership quality.   
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Implications for practice 
There are potential opportunities to improve the care of individuals living with CVD and ED. 
One such opportunity is how healthcare providers discuss ED (refer to Box 1 and 2).  The 
terminology used by healthcare professionals to describe ED may not be understood by all 
patients. For example ͚EƌeĐtile dǇsfuŶĐtioŶ͛ does Ŷot tƌaŶslate diƌeĐtlǇ iŶto otheƌ laŶguages, 
such as Bengali. Therefore an alternative term may be needed (Steggall, 2012). Difficulties 
such as language barriers as well as cultural differences can therefore create difficulties for 
clinical practitioners to identify ED. Byrne et al (2013) suggest that patients not only report 
that they would find it easy to discuss sexual issues with their healthcare provider but also 
report a desire for more opportunity during consultations to discuss sexual issues. This 
indicates that healthcare professionals could create an environment in which issues around 
sexuality can easily be raised and discussed. This may mean that specific training should be 
offered in order for healthcare professionals to possess the awareness and skills to facilitate 
this in clinic.  Clinicians unused to assessing sexual dysfunction may find the assessment 
guide helpful to identify the severity and nature of the problem (refer to Box 2). 
 
Research also highlights the importance of involving the patient͛s partners, where possible, 
in the rehabilitation process. This not only provides an opportunity for the clinician to have 
aŶ uŶdeƌstaŶdiŶg of hoǁ ED ŵaǇ ďe iŵpaĐtiŶg oŶ a patieŶts͛ ƋualitǇ of life aŶd that of their 
partner; it also permits a discourse to emerge in which ED aŶd the Đouple͛s iŶtiŵate 
relationship can be discussed.  
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Implications for research 
Research and anecdotal evidence suggests an association between ED and adherence to 
CVD medication. However, the strength and direction of that relationship has not been 
confirmed. Further research needs to be carried out in order to investigate the prevalence 
of non-adherence to cardiac medication in those with ED as well as how treatment for ED 
and beliefs about these co-morbid conditions influence adherence behaviour. By identifying 
the demographic, clinical and psychosocial factors which predict adherence to CVD 
treatment only then can research begin to look at the possibility of designing a behaviour 
change intervention aimed at improving adherence.   
 
Conclusion 
There is a growing body of literature indicating that men with CVD either cease taking their 
prescribed medications, or miss doses; this may be related to the common side effect of 
reduced erectile strength. Non-adherence poses significant risk to these men, in terms of 
morbidity and mortality, but also in terms of their sexual relationship. Opportunities have to 
be created to facilitate discussions of adherence and ED, and these can be facilitated by 
using the IIEF-5 either at the point of prescribing CVD medication or during the annual 
medication review. Where ED has been identified, patients will need to be assessed for the 
severity of their ED and appropriate treatment instigated.  
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Box 1. Creating the opportunities for discussing ED 
Ask: ͚“oŵe ŵeŶ ǁho aƌe takiŶg ŵediĐatioŶ foƌ ĐaƌdioǀasĐulaƌ disease ŵaǇ haǀe tƌouďle 
with erections. If you have any questions or would like to discuss that, I can arrange an 
appoiŶtŵeŶt foƌ Ǉou͛ 
Awareness: Posters informing men of the prevalence of ED can be used to create the 
environment where questions can be asked 
Inform: ED is common. There are several treatment options that can be considered. If you 
want to discuss these options, speak with your clinician, GP, pharmacist, or visit websites 
such as www.menshealthanswers.co.uk  
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Box 2. 5-item International Index of Erectile Function (IIEF-5) Adapted from Rosen, et al. 
(1999) 
How do you rate your confidence that you could get and keep an erection? 
Very low 
1 
Low 
2 
Moderate 
3 
High 
4 
Very high 
5 
When you had erections with sexual stimulation, how often were your erections hard 
enough for penetration? 
Almost 
never/Never 
1 
A few times (much 
less than half the 
time) 
2 
Sometimes (about 
half the time) 
3 
Most times (much 
more than half the 
time) 
4 
Almost 
always/always 
5 
During sexual intercourse, how often were you able to maintain your erection after you 
had penetrated (entered) your partner? 
Almost 
never/Never 
1 
A few times (much 
less than half the 
time) 
2 
Sometimes (about 
half the time) 
3 
Most times (much 
more than half the 
time) 
4 
Almost 
always/always 
5 
During sexual intercourse, how difficult was it to maintain your erection to completion of 
sexual intercourse? 
Extremely difficult 
1 
Very difficult 
2 
Difficult 
3 
Slightly difficult 
4 
Not difficult 
5 
When you attempted sexual intercourse, how often was it satisfactory for you? 
Almost 
never/Never 
1 
A few times (much 
less than half the 
time) 
2 
Sometimes (about 
half the time) 
3 
Most times (much 
more than half the 
time) 
4 
Almost 
always/always 
5 
Score _____  
 
The IIEF-5 score is the sum of questions 1 to 5. The lowest score is 5 and the highest score 
25. If the score is 21 or less you may be showing signs of erectile dysfunction (ED). Please 
speak with the person who gave you this form, or ask your GP for advice. 
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Figure 1 Integrated model of depression, erectile dysfunction and cardiovascular disease 
Adapted from (Goldstein, 2000) 
 
